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Currently no speciﬁc biomarkers exist for the screening of pregnancies at risk for down syndrome (DS). Since a quantitative
proteomic approach with isobaric labelling (iTRAQ) has recently been suggested to be highly suitable for the discovery of novel
plasma biomarkers, we have now used this method to examine for potential quantitative changes in the plasma proteome of the
pregnancies bearing DS fetuses in comparison to normal healthy babies. In our study, we used plasma from six women with DS
pregnancies and six with uncomplicated pregnancies care were taken to match cases and controls for gestational and maternal age,
as these could be a confounder. In our quantitative proteomics analysis we were able to detect 178 proteins using iTRAQ labelling
in conjunction with 4800 MALDI TOF/TOF. Amongst these we observed changes in βHCG, a known screening marker for DS,
indicating that our assay was functional. We found a number of elevated proteins Ig lambda chain C region, serum amyloid P-
component, amyloid beta A4, and under expressed proteins like gamma-actin and titin in DS pregnancies. These proteins are also
found in the sera of patients with Alzheimer disease, which share similar pathologies of DS. Our study therefore indicates that the
iTRAQ labelling approach may be indeed useful for the detection of novel biomarkers.
1.Introduction
Down syndrome (DS) is the most common chromosomal
aneuploidy in live births and a leading cause of mental
retardation. Prenatal detection of chromosomal anomalies,
such as trisomy 21, in cases with DS relies on invasive
practices such as amniocentesis or chorionic villi sampling.
These procedures are associated with a risk of fetal loss or
adverse pregnancy outcome [1]. Furthermore, it requires
special facilities and highly trained staﬀ. For this reason
alternative strategies are sought, such as the noninvasive
prenatal diagnosis of fetal genetic anomalies via the analysis
of rare traﬃcking fetal cells [2] or cell-free fetal nucleic acids
in maternal blood [3]. As this long sought goal has not yet
reached clinical implementation [4], current clinical practice
relies on a series of screening steps aimed at detecting at-
riskpregnancies.Inmanycentresthescreeningprocedurefor
DS is carried out in the late ﬁrst and early second trimester
(11–14 weeks of gestation) and involves a combination of
ultrasound and serum marker analysis [5]. Although the
eﬃcacy of this method has improved considerably, and is
more accurate than previous second trimester screening
approaches, it is hampered by the skill and precision of the
ultrasonographer and external factors such as ethnicity or
other factors, such as assisted reproductive technologies.
Hence, it is obvious that new tools are needed to improve
current state of the art. One such strategy is to look
for new potential biomarkers using noninvasive proteomic
approaches. The rationale for this strategy is that placentae
fromfetuseswithDS,especiallythevilli,aremorphologically
distinct from the placentae of euploid fetuses, a feature
attributed to altered aberrant protein expression [6]. As
the placenta, a large organ with rapid cell turn-over is
in direct contact with the maternal circulation, proteins2 Journal of Biomedicine and Biotechnology
Table 1: Patients with and without a down syndrome pregnancy at
the time of screening n = 6.
First trimester
DS Control
Maternal age (years) 35.8 ± 4.33 5 .1 ± 4.1
Gestational age (weeks) 12.4 ± 1.21 2 .5 ± 1.1
released by it should be detectable in maternal plasma,
and could consequently serve as promising markers for
abnormal placentation involved in a number of pregnancy
related disorders. In this regard, preliminary proteomic
investigations have shown that quantitative alterations in
protein expression are found to occur in the amniotic ﬂuid
[7, 8] and maternal serum of pregnancies with fetuses
aﬀected with down syndrome, and that these could serve as
new potential biomarkers [9].
Unfortunately none of these studies used quantitative
approaches of the type that permit precise assessment of
the extent of up- or down-regulation of the proposed
biomarkers. As such, it will be diﬃcult to validate these in
blinded studies of clinical serum or plasma samples, a crucial
facet in determining their speciﬁcity [9–11].
These studies are further complicated by the complex
nature of the plasma/serum proteome, whereby the majority
of low abundance proteins are masked by the preponderance
of a few highly abundant proteins. This high dynamic
range [12]e ﬀectively precludes the use of more conven-
tional proteomic strategies, such as those employing gel
electrophoresis with or without or ﬂuorescent labelling,
for example, Diﬀerence Gel Electrophoresis (DIGE). This
deﬁcit renders the identiﬁcation of potential biomarkers
in plasma/serum by conventional comparative proteomic
approaches very challenging.
For this reason an approach using Isobaric Tags for
Absolute and Relative Quantitation (iTRAQ) has been
proposed for the discovery of plasma biomarkers [13]. This
chemical labelling method involves the stable incorporation
of isotopes into an amine tagging reagent, which can be
reliably detected by mass spectrometry, thereby permitting
comparative quantitation in a multiplex manner. Currently
4-plex and 8-plex reagents are commercially available, which
are used to label the protein samples of interest following
trypsin digestion. The use of diﬀerent isobaric tags implies
t h a tu pt o4o r8d i ﬀerent samples, one of which serves as a
reference, can be examined simultaneously in a single mass
spectrometric analysis. It is for this reason that the iTRAQ
approach has been suggested to be suitable for the discovery
of biomarkers in a wide range of body ﬂuids and tissues,
including plasma.
In order to examine whether this approach would be
suitable for the detection of potential biomarkers for down
syndrome, we performed a proof-of-principle experiment,
in which we examined samples from 6 cases with down
syndrome in comparison to 6 matching controls. In our
study we have used a 4-plex iTRAQ labelling in conjunction
with a 4800 MALDI TOF/TOF approach to examine plasma
samples obtained in ﬁrst trimester pregnancies. Our results
indicatethatquantitativediﬀerencescanbedetectedbetween
aneuploid samples and samples from euploid pregnancies
and that such alteration may reﬂect upon changes known to
occur in down syndrome.
2.MaterialsandMethods
2.1. Samples. Blood samples for this case-control proteome
study were collected from six pregnant women carrying a
DS fetus (11–13 weeks of gestation) and six pregnant women
withnormaleuploidpregnancies.Thesampleswerematched
for maternal and gestational age (Table 1). This study was
undertaken with the approval of the Institutional Ethical
Board of the University Hospital, Basel, Switzerland and
written informed consent was required in all instances.
2.2. Sample Preparation. 9mL blood was drawn into BD
P100 tubes (BD Diagnostics, Franklin Lake, NY, USA),
which are specially designed for proteomics experiments,
in that the Ethylenediaminetetraacetic acid (EDTA) and
protease inhibitor present in the tube prevent coagulation
and stabilize the plasma proteome. Following phlebotomy
the samples were centrifuged at 3000×gf o r3 0m i n u t e sa t
10◦C, whereby the plasma was separated from the cellular
fraction by aid of a mechanical separator. 100μL aliquots
were stored at −80◦C until further use. For an overview of
the work-ﬂow used in this analysis refer to Figure 1.
2.3. Immunodepletion of High-Abundance Plasma Proteins.
Highly abundant plasma proteins were depleted using Pro-
teoMiner Protein Enrichment Kit (Bio-Rad Laboratories,
Inc.) [14], as per the manufacturer’s instructions. 1mL of
plasma was used for the depletion and after the whole
procedure, 300μL was eluted in elution reagent. After
depletion protein concentration was measured by using RC-
DC Protein assay kit (Bio-Rad Laboratories, Inc.)
2.4. Trypic Digestion and iTRAQ Reagent Labelling. Equal
amounts (100μg) of depleted plasma protein from six
of the DS cases and controls were pooled separately in
duplicate for the iTRAQ labelling. These samples were
denatured with 2% SDS in 500mM triethylammonium
bicarbonate(TEAB)(Sigma-Aldrich)for15minutesatroom
temperature, following which they were reduced with 2μL
of 50mM tri-(2-carboxyethyl) phosphine (TCEP) (Sigma-
Aldrich) at 60◦C for 1 hour and were then alkylated
with 10mM s-Methylmethanethisulfonate (MMTS) for 10
minutes in room temperature. After alkylation, the proteins
were digested overnight at 37◦Cw i t h1U / μL trypsin (TPCK
treated) (Applied Biosystems, Foster City, CA 94404, USA).
Peptides were labelled with one unit of iTRAQ Reagent
Multi-plex kit (Applied Biosystems, Foster City, CA 94404,
USA) that was reconstituted in 70μL of ethanol. iTRAQ
labels 114, 116 were used separately for labelling the pooled
duplicated control sample and 115, 117 were used separately
to label the pooled duplicate down syndrome samples. The
iTRAQ labelling reagent solution was added to the digest
and incubated for 1 hour at room temperature. To assess theJournal of Biomedicine and Biotechnology 3
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Figure 1: Workﬂow for quantitative proteomics using iTRAQ
reagent. Equal amounts of plasma protein (100μg) from control
and DS (n = 6) were pooled separately and duplicated, controls
were labeled with 114 and 116 iTRAQ label and DS was labeled
with 115 and 117 iTRAQ label. The labeled samples were pooled
and were subjected to a strong cation exchange chromatography
to remove the excess label. Afterwards LC-MALDI MS/MS was
performed for protein identiﬁcation and quantiﬁcation.
accuracy of the ratiometric quantitation of iTRAQ reagent a
split in signal was performed and the data were corrected as
described in detail by Unwin and colleague [15].
2.5. Strong Cation Exchange Chromatography (SCX). Strong
cation exchange chromatography was preformed to remove
the excess iTRAQ reagent and interfering substances for the
mass analysis. Dried peptides were resuspended in 200μL
of Buﬀer A and were loaded on Poly Sulfoethyl A Column
(200mm length × 4.6 id, 5μm particle size, 200 pore size) on
a BioLC HPLC unit (Dionex). Buﬀer A consisted of 10mM
KHPO4 and 25% acetonitrile, 500mM KCl, pH 3.0, and
Buﬀer B consisted of 10mM KH2PO4, 25% acetonitrile, and
500mM KCl pH 3.0. The 60 minutes gradient comprised
of 100% Buﬀer A for 5 minutes, 5%–30% Buﬀer B for
40 minutes, 30%–100% Buﬀer B for 5 minutes, 100%
Buﬀer B for 5 minutes, and ﬁnally 100% Buﬀer A for
5 minutes. Ten fractions were collected using a Foxy Jr.
Fraction Collector (Dionex). Subsequently, these fractions
were pooled according to the chromatogram proﬁle based
on the peak intensity and the products dried in a vacuum
concentrator, after which they were stored at −20◦Cp r i o rt o
mass spectrometric analysis.
2.6. Nano LC MALDI. The dried SCX iTRAQ-labeled pep-
tides were dissolved in Buﬀer A which consist of 95% H2O,
5% acetonitrile, 0.1% TFA and were loaded on C18 trap
column (1mm × 300μm i.d. column) at 30μL/minutes
and separated on an analytical column (150mm ×100μm
i.d. column) at 500nL/min using the LC-packing Ultimate
system. The peptides were separated using a linearly increas-
ing concentration of acetonitrile in Buﬀer B from 5% to
30% in 120 minutes, and from 30% to 60% in 40 minutes.
The elute was mixed with matrix (2mg/mL alpha-cyano-4-
hydroxycinnamic acid in 80% acetonitrile, and 0.1% TFA)
at a ﬂow rate of 800nl/min and deposited on an Opti-
TOF LC/MALDI (Applied Biosystems) plate in 10S fractions,
using an automatic robot (Probot, Dionex).
2.7. MS and MSMS. The Mass spectrometer 4800 plus
MALDI TOF/TOF Analyzer (Applied Biosystems) was set
to perform data acquisition in positive ion mode. An MS
condition of 1000 shots per spectrum was used. Monoiso-
topic precursor selection for MS/MS was done by automatic
precursor selection using an interpretation method using
the 12 most intense peaks per spot with an MS/MS mode
condition of 4000 laser shots per spectrum. Minimum peak
width was one fraction and mass tolerance was 80ppm.
A d d u c tt o l e r a n c ei s( m/z) ± 0.003. MSMS was done with a
gas pressure of 2×10
−2 bar in the collision cell. Air was used
as collision gas.
2.8. Protein Identiﬁcation and Database Searches. Protein
identiﬁcation and quantiﬁcation was done by using the
ProteinPioltsoftwarev2.0(AppliedBiosystems;MDS-Sciex).
The search was performed against the Human database of
UniProtKB/Swiss-Prot (Version 3.50) from the EBI website
(http://www.ebi.ac.uk./IPI/IPIhelp.html) and concatenated
target-decoy database search strategy was used to check the
false positive rate [16] in our case it was found to be 0%,
which boosted the reliability of our data.
2.9. Relative Quantitation Criteria. The Paragon algorithm
[17, 18] in ProteinPiolt v2.0 software was used as the default
search program with digestion enzyme set as trypsin and
methyl methanethiosulfonate as cysteine modiﬁcation. The
search also included the possibility of more than eighty
biologicalmodiﬁcationsandaminoacidsubstitutionofupto
two substitutions per peptide using the BLOSUM 62 matrix.
Data were normalized for loading error by bias correction
calculated with Progroup algorithm Identiﬁed proteins with
at least 95% conﬁdence and with a ProtScore of 1.3, were
reported. The results obtained from ProteinPiolt software
v2.0softwarewereexportedtoMicrosoftExcelforthefurther
analysis. The study was performed in double duplex manner,
where DS samples were labelled with 115 and 117, control
were labelled with 114 and 116. Peptides were selected based
on the criteria deﬁned in the protein pilot software, which
means all the peptides were included for quantitation with4 Journal of Biomedicine and Biotechnology
an exception for those without an iTRAQ modiﬁcation or
reporter ion, an area count less than 40 and peptides with
P value less than .001 were excluded [19]. As described by
Gan and colleague in their study on estimation of relative
quantitative ratio from iTRAQ experiments, we also used
only peptides above or equal to 70% conﬁdence level for the
estimation of relative quantitation [20].
2.10. PANTHER Analysis. The PANTHER database was used
to elucidate the molecular function, biological process and
signaling pathway associated with each individual protein
(http://panther.appliedbiosystems.com/).
3. Results
Samples were obtained from 6 cases with a conﬁrmed
DS fetus and 6 samples from normal euploid singleton
pregnancies. Care was taken to match both maternal and
gestational age, to rule out any confounding inﬂuence of
these two parameters.
Low abundant plasma proteins were enriched by using
ProteoMinerProteinEnrichmentKit.Thiswasaccomplished
through the use of a large, highly diverse bead-based library
of combinatorial peptide ligands. When plasma was applied
to the beads, a small fraction of the high abundance
proteins saturated their high aﬃnity ligands and the excess
high abundance proteins were washed away. In addition a
very small amount of high abundance proteins and low
abundance proteins were concentrated on their speciﬁc
aﬃnity ligands. This provides for a signiﬁcant enrichment of
medium and low abundant plasma proteins.
The samples were pooled separately in and duplicate
in order to have more precise analytical replicate measure-
ments. The iTRAQ analysis was done in double duplex style,
the DS samples were labelled with iTRAQ 115 and 117 and
the control samples with iTRAQ 114 and 116, using the
work-ﬂow illustrated in Figure 1.
Following tandem MS MS, and by focussing on iTRAQ
reporter ions in low molecular mass range (114–117Da)
for quantiﬁcation, we identiﬁed 235 proteins with ≥95%
conﬁdence. However, after manually rechecking the MS/MS
data thoroughly peak by peak, only 187 out of 235 pro-
teins (78.5%) had a relative quantitation derived from the
analysis of two or more peptides, while for 45 proteins, the
quantitation was based on single peptide. For 3 proteins no
quantitation could be ascertained by analysis using Protein
Pilot. Figure 2 shows the MSMS spectrum of the precursor
([M+ H]+, m/z 1527.7Da). In low-mass region the reporter
ions, are seen while area under the curve was used for
quantiﬁcation.
As we did the experiment in double duplex manner, DS
(115 and 117) and control (114 and 116), it was possible to
estimate the cutoﬀ point for diﬀerentially expressed protein
in our sample [19, 20]. Based on 187 relative abundant
protein ratios from DS and control sample, an average
variation of 4.4% (±0.04) was measured. If the cutoﬀ was
set at 5% average variance then only 72% of the proteins
would fall with in this variation range, but. If the range was
(ii) (i)
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Figure 2: Components of the spectrum illustrated are (i) MSMS
spectrum of the precursor ([M + H] +, m/z 1527.7 Da). (ii) low-
mass region showing the reporter ions used for quantitation. The
peptide is labeled by isobaric tags at both the N terminus and C-
terminal lysine side chain. The precursor ion and all the fragment
ions therefore contain all four members of the tag set, but remain
isobaric.TheMSMSspectrumwasobtainedfromthesinglycharged
[M + H] + peptide using a 4800 MALDI TOF-TOF analyzer.
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Figure 3: Frequency distribution (bars) from both DS and control
replicates across diﬀerent ranges of variation. The cumulative
percentage (lines) is deﬁned as the cumulative number of proteins
falling within the deﬁned variation range against the total number
of protein.
increased to 20% then about 92% of the protein falls in this
variation range as illustrated in Figure 3. So the cutoﬀ point
in this experiment was set at 20% (±0.2). That means any
relative change in protein ratio below or above ±1.2 fold was
considered as diﬀerentially under or over expressed.
Thefunctionaldistributionoftheseproteinsisillustrated
in Figure 4. For this interpretation, an analysis of 235
proteins was performed using the PANTHER classiﬁcation
system, which sorts the proteins into respective classes based
on their biological process.
It is of interest that two of the major groups involve cell
adhesion molecules (13%) and extra cellular matrix proteins
(18%) and member of the protease family, factors that are
knowntobeaberrantindownsyndrome.FurthermorelargeJournal of Biomedicine and Biotechnology 5
Table 2: List of the protein identiﬁed as up-regulated from the iTRAQ experiment, indicating is the biological process and molecular
function of these proteins. (P value. 001).
No. Acc. number % Cov Protein name Biological processes Molecular functions
1 P20742 31.5 Pregnancy zone protein Ligand-mediated
signaling
Other cytokine
2 P04003 30 C4b-binding protein
alpha chain
Complement-
mediated
immunity
Complement
component
3 P01842 68.6 Ig lambda chain C
regions Immunity Immunoglobulin
4 P01233 26.1 Choriogonadotropin
subunit beta mRNA transcription
Other signaling
molecule
5 P43251 14.1 Biotinidase Vitamin metabolism Other hydrolase
6 P01834 84 Ig kappa chain C
region Immunity Immunoglobulin
7 P01859 42 Ig gamma-2 chain C
region Immunity Immunoglobulin
8 P01215 6 Glycoprotein
hormones alpha chain
Protein targeting
and localization
SNARE protein
9 P80108 16.5 Phosphatidylinositol-
glycan
Intracellular
signaling cascade
Lipase
10 P01860 53.8 Ig gamma-3 chain C
region
B-cell- and
antibody-mediated
immunity
Immunoglobulin
11 Q9UGM5 27.5 Fetuin-B Intracellular
signaling cascade
Lipase
12 P35858 26 Insulin-like growth
factor Cell adhesion Receptor
13 P26927 22.9 Hepatocyte growth
factor-like protein
Ligand-mediated
signaling
Growth factor
14 P02751 49.4 Fibronectin Extracellular matrix
protein
Cell adhesion
molecule
15 P02743 54.3 Serum amyloid
P-component
Amino acid
biosynthesis
Synthase
16 P00751 37.7 Complement factor B Proteolysis Serine protease
17 P01031 42.6 Complement C5
Complement-
mediated
immunity
Complement
component
18 P07358 36.5
Complement
component C8 beta
chain
Complement-
mediated
immunity
Complement
component
19 P02790 67.3 Hemopexin Vitamin/cofactor
transport
Carrier protein
20 P00734 61.3 Prothrombin Blood clotting Serine protease
21 Q14624 54.8
Inter-alpha-trypsin
inhibitor heavy chain
H4
Proteolysis
Serine protease
inhibitor
22 O00213 10.8 Amyloid beta A4 Other neuronal
activity
Other signaling
molecule
23 P08603 61.7 Complement factor H
Complement-
mediated
immunity
Complement
component
24 P00738 53 Haptoglobin Neurotransmitter
release
Vesicle coat protein6 Journal of Biomedicine and Biotechnology
Table 2: Continued.
No. Acc. Number % Cov Protein name Biological processes Molecular functions
25 P22891 10.3 Vitamin K-dependent
protein Z Proteolysis Serine protease
26 P22792 14.1 Carboxypeptidase N
subunit 2 Cell surface receptor Receptor
27 P07357 27.9 Complement
component C8
Complement-
mediated
immunity
Complement
component
28 P02741 8.9 C-reactive protein Stress response
Defense and
immunity
Transporter 2%
Cell adhesion 
molecule 13%
Defense/immunity 
protein 18%
Extra cellular 
matrix 18%
Hydrolase 7%
Molecular function 
unclassified 5%
Protease 9%
Receptor 5%
Calcium binding 
protein 2%
Regulatory 
molecule 4%
Signaling molecule
13%
Transfer/carrier 
protein 4%
Figure 4: Number of plasma protein identiﬁed using iTRAQ reagent. In total, 235 proteins were identiﬁed. Shown above is the classiﬁcation
of these protein in diﬀerent category based on molecular function.
groupswerefoundtoinvolvesignallingmolecules(13%)and
18% defense/immunity proteins.
Of the large group of signiﬁcantly up-regulated proteins,
it is highly noteworthy that this includes βHCG (Beta
human chorionic gonadotropin), a subunit of the human
chorionic gonadotropin protein known to be elevated in
pregnancies [5] with DS fetuses, and which forms one of
the backbone of current screening programs in the ﬁrst
trimester. This ﬁnding, therefore strongly suggests, that the
iTRAQ method we have chosen appears to be able to identify
relevant proteins (Table 2 ). In this group, elevations were
also recorded for pregnancy zone protein (PZP) (P20742),
thereby indicating that our assay is indeed detecting proteins
of placental origin. Elevation of two members of the amyloid
family (Serum amyloid P-component and Amyloid beta A4)
was also observed, which could be a signiﬁcant ﬁnding, as
these proteins have been suggested to play a role in the
dementia found to occur in adult DS patients. An elevation
in the inﬂammatory response marker, C-reactive protein
and members of the immunoglobulin family like Ig lambda
chain C region was also noted, which could be indicative
of an increased inﬂammatory response in DS pregnancies.
phosphatidylinositol-glycan (P80108), Insulin-like growth
factor (P35858) is involved in protein-protein interactions
that result in protein complexes and hepatocyte growth
factor (P26927) was also prominent amongst the list of the
up-regulated proteins.
Amongst the group of down-regulated proteins (Table 3)
were a number of molecules involved in cell adhesion and
extracellular matrix including titin (Q8WZ42), basement
membrane speciﬁc heparan sulfate proteoglycan (P98160),
actin,cytoplasmic2(Gamma-actin)(P63261)andﬁbrinogen
alpha chain (P02671). This observation could be important
as changes in tissue elasticity are a hallmark of DS cases,
and play signiﬁcant role in their detection by ultrasound via
the presence of an increased neck fold (nuchal translucency).
peroxiredoxin 2 (PRDX2), an antioxidant enzyme, is under-
expressed in DS fetal brain and dynein heavy chain 9, was
also noted in our list of down regulated proteins.
The PANTHER database was used for the pathway
analysis on the proteins which were shown to be over or
under expressed in our study. It was interesting to note thatJournal of Biomedicine and Biotechnology 7
Table 3: List of the protein identiﬁed as down regulated from the iTRAQ experiment, indicating is the biological process and molecular
function of these proteins. (P value .001).
No. Acc. number % Cov Protein name Biological processes Molecular functions
1 P01009 32.8 Alpha-1-antitrypsin
Nerve-nerve
synaptic
transmission
Glutamate receptor
2 P02768 67 Serum albumin Amino acid
biosynthesis Reductase
3 P63261 49.1 Actin, cytoplasmic 2
(Gamma-actin) Cell structure Actin and actin
related protein
4 O95445 32.4 Apolipoprotein M
(Apo-M) Lipid transport Plasma protein
5 P06727 67.7 Apolipoprotein A-IV Lipid and fatty acid
transport Transporter
6 P02775 41.4 Platelet basic protein Pyrimidine
metabolism Phosphorylase
7 P02647 85.8 Apolipoprotein A-I Lipid and fatty acid
transport Transporter
8 P01023 39.8 Alpha-2-
macroglobulin
Developmental
processes
Serine/threonine
kinase
9 P02787 58.9 Serotransferrin Amino acid
biosynthesis Synthase
10 P04275 11.3 von Willebrand factor Cell adhesion Extracellular matrix
glycoprotein
11 P02671 35.2 Fibrinogen alpha chain Cell proliferation
and diﬀerentiation
Extracellular matrix
glycoprotein
12 P01024 29.6 Complement C3
Nerve-nerve
synaptic
transmission
Glutamate receptor
13 P98160 5.1 Heparan sulfate
proteoglycan Extracellular matrix Cell adhesion
mediated signal
14 P51884 33.4 Lumican Receptor
Cell
adhesion-mediated
signaling
15 P04114 41.5 Apolipoprotein B-100 Lipid and fatty acid
transport
Component of
serum lipoproteins
16 Q8WZ42 9.5 Titin (EC 2.7.11.1)
(Connectin) Muscle contraction Actin binding
cytoskeletal protein
17 P08519 11 Apolipoprotein(a) Cell proliferation
and diﬀerentiation Peptide hormone
18 P43652 47.7 Afamin Transport
Other
transfer/carrier
protein
19 P06396 54.9 Gelsolin Cell structure Nonmotor actin
binding protein
20 P02749 54.2 Beta-2-glycoprotein 1 Amino acid
metabolism Transaminase
21 Q9NYC9 4.8 Dynein heavy chain 9 Force generating
protein ATPase activity
22 P32119 4 Peroxiredoxin-2 Redox regulation Eliminating
peroxides
13.3% proteins identiﬁed in the DS sample correspond to
proteins found in the Alzheimer disease-amyloid secretase
and Alzheimer disease-presenilin pathways illustrated in
Figure 5.This indicates that these pathways should be more
closely studied in conjunction with DS. More than the 40%
of the protein we identiﬁed in DS samples correspond to
proteins in the Integrin signalling pathway. This might be
due to the fact that cell adhesion molecules and extra cellular
matrix protein represent 13% and 18% of the total proteins
identiﬁed, respectively as illustrated in Figure 4.8 Journal of Biomedicine and Biotechnology
Blood coagulation (20%)
Integrin signalling (46.7%)
Thyrotronin-releasing 
harmone receptor signalling (6.7%)
Alzheimer disease-
amyloid secretase (13.3%)
Alzheimer disease-
presenilin (13.3%)
Figure 5: PANTHER analysis for pathway.I nt o t a l ,2 8p r o t e i n sw e r e
identiﬁed as elevated and 22 proteins were under expressed. Shown
above is the diﬀerent signaling pathways hits by these protein.
4. Discussion
QuantitationofserumorplasmaproteinsviaiTRAQanalysis
has recently been suggested to be suitable for the detection
of biomarkers, as the method is highly reproducible, with
little run-to-run variation. This aspect, which is optimal
to embark on such a “ﬁshing-expedition”, is actually quite
surprising, granted the large number of individual steps in
the work-ﬂow. This conclusion was, however, derived at
after a lengthy comparison involving three pools of case and
control samples, as well as a number of individual samples,
where a coeﬃcient of variation of 11.7% was noted [21].
In a preliminary proof-of-principle experiment, we have
now assessed whether this method could be suitable for the
detection of biomarkers useful for DS screening. From our
small-scale preliminary evaluation we identiﬁed over 200
proteins whose concentration was altered in the plasma of
pregnancies with a DS fetus when compared to those with
euploid fetuses.
It is of interest that βhCG is detected in the pool of
proteins found to be elevated. This glycoprotein, which is
produced early in pregnancy by the developing embryo
and subsequently by the syncytiotrophoblast, forms the
backboneof1stand2ndtrimesterscreeningstrategies.Inthe
1st trimester, pregnancies at-risk of carrying a fetus aﬀected
by DS are identiﬁed on the basis of an almost 2 fold MoM
(Multiples of the Median) elevation in βhCG. The presence
of this important screening marker in our pool of elevated
plasma proteins suggests that the strategy we have chosen for
theidentiﬁcationofnewbiomarkersisfunctionalandworthy
of further pursuit.
In this context it is worth noting that this marker was
not detected in two previous studies [9, 11] using proteomic
technologies for the identiﬁcation of protein markers for
DS in maternal plasma or serum. This could be due to
limitations in detection sensitivity of the 2D gel approach
these studies had used.
That our assay is indeed detecting proteins of placental
origin is illustrated by presence of pregnancy zone protein
which is a glycoprotein and a proteinase inhibitor which
derive its importance in pregnancy by playing potential role
in preventing the attack from maternal immune system on
the developing fetus which can be seen as foreign allograft
[22].This protein was amongst our list of up-regulated
proteins, which is similar to alpha 2-macroglobulin, is quan-
titatively the most important pregnancy-associated plasma
protein.
Amongst the pool of up-regulated proteins were serum
amyloid P-component and amyloid beta A4, which is
encouraging as members of this family have found to be
elevated in previous studies on pregnancies with DS fetuses,
which may be a reﬂection of an altered gene expression
pattern associated with DS-related dementia. It is also
important to note that the amyloid precursor protein (APP)
gene is located in DS region of chromosome 21. Teller
and colleagues have shown that a relatively minor from of
amyloid beta protein was present in the brain of DS aﬀected
pregnancy as early as in late 2nd trimester [23].
Elevations in a number of inﬂammatory molecules,
most of which are probably of maternal origin, may be a
reﬂection of the elevated release of placental debris which
has been suggested to occur in pregnancies with DS fetuses.
Phosphatidylinositol-glycan is expressed in the placental
tissue [24], also involved in many cellular process and plays
important role in several signal transduction pathways.
Of the down-regulated proteins like actin, gelsolin,
heparan sulfate proteoglycan [25], and ﬁbrinogen alpha
chain, it is noteworthy that all these protein are involved in
cell adhesion, extracellular matrix, cell structure or muscle
contraction,sinceDSfetusesareknowntoexhibitconnective
tissue abnormalities [26], the most pronounced of which is
the increased neck fold (nuchal translucency). Since adult
DS patients are prone to skeletal muscle deﬁciency, our
ﬁnding concerning reduced titin plasma levels is intriguing,
as this very large protein plays an important role in muscle
contraction. In one of recent study Du and colleague [27]
have shown trophoblast expression of titin in ﬁrst trimester
placentae.
Only a limited number of studies have attempted to use
proteomic approaches for the discovery of new biomarkers
for pregnancies at-risk of carrying a fetus with DS, two of
these used 2-DE approaches [9, 11], while a further used
a SELDI method [10]. Study of the former studies that
by Nagalla and colleagues is the largest, having examined
serum samples from 56 pregnant women. This study used
samples collected in both the 1st and 2nd trimester of
pregnancy, which were recruited as part of the NIH funded
FASTER study, and largely made use of the ﬂuorescent
2D-DIGE process. In their study, 18 proteins were found
to be elevated in 1st trimester samples, which included
members of the apoliprotein family, clusterin and proteins
involved in skeletal development (tetranectin). The study byJournal of Biomedicine and Biotechnology 9
Kolialexi and colleagues [11] used traditional 2DE stained
with Coomassie blue on 20 maternal plasma samples (8
cases, 12 controls, 16–18 weeks of pregnancy), by which
means 8 candidate proteins were detected. Elevations were
noted for apoliprotein E and serum amyloid P-component.
IncontrasttothestudybyNagallaetal.[9]adownregulation
for clusterin was noted.
In the study by Busch and colleagues [10] using a SELDI
a p p r oa c h ,tra c e sw e r en o t e dwh i c hd i ﬀered between DS cases
and controls. However, no attempt was made to discern
what proteins were responsible for these altered patterns, nor
was any detailed description provided of how they could be
reproduced.
Other than common elevation in serum amyloid and
complement component families, little commonality exists
between our study and these studies. This may be due to
a number of factors including, limited study size, time of
samplingcollection,sampleprocessingandstorage,aswellas
use of very diﬀerent technical approaches. In our follow-up
studies we would like to validate these putative biomarkers
usingimmunoblotandEnzymelinkedimmunosorbentassay
(ELISA).MorerecentlySelectedReactionMonitoring(SRM)
[28] has evolved as a method of choice for validation of
biomarkers using mass spectroscopy.
The increasing popularity of the iTRAQ approach due
to its reproducibility and robustness, including studies
for cancer or inﬂammatory autoimmune disorder speciﬁc
biomarkers suggests that it will become the method of
choice for future studies, until it is surpassed by a new
technical development. As pregnancy represents a unique
constellation, whereby a foreign being is supported and
nourished by the host, it may serve as an ideal model for
proteomic analyses, as any unique markers should ideally
disappear post delivery. Furthermore, as very few speciﬁc
biomarkers exist to assist with the screening of a number
of pregnancy-related disorders, especially preeclampsia or
preterm labour, it is likely that this will become the focus of
considerable research attention in the near future.
5. Conclusion
In this report we conclude that isobaric labelling technique
is a suitable approach for the quantitative detection of new
screening biomarkers in the plasma of pregnancies with
a DS fetus compared to those with euploid fetuses. In
this preliminary proof-of-principle study, we were able to
detect quantitatively under- or over-expressed proteins. In
the future additional studies, using larger sample sizes will
be required to identify a panel of biomarkers which can be
used in screening for DS pregnancies.
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